Amgen Inc PEG Ratio

Data as of August 04, 2026

How It's Calculated

What This Means

Amgen Inc's PEG ratio of 3.43 is above 2, suggesting the stock may be overvalued relative to its growth rate. Investors are paying a premium for each unit of earnings growth.

About Amgen Inc

Amgen Inc (AMGN) operates in the Biotechnology sector, specifically in Biotechnology. With a market capitalization of about $207.87B, it ranks as a mega-cap stock — one of the largest publicly traded companies.

Shares recently traded near $378.87, within a 52-week range of $269.77 to $398.00 (-4.8% from the high, +40.4% from the low). Beta of 0.42 indicates relatively lower volatility versus the market.

Trailing profit margin is about 21.0%, signaling a solid profit margin for its industry.

Understanding This Metric

The PEG ratio adjusts the PE multiple for expected earnings growth, helping compare fast-growing and slow-growing names on a more equal footing. For Amgen Inc, a PEG near 1 is often described as fairly valued relative to growth, though the growth estimate itself can change quickly with guidance revisions.

Sector Comparison

Among Biotechnology names on our S&P 100 coverage, Amgen Inc's PEG ratio of 3.43 can be compared with peers such as GILD (3.59), REGN (0.86). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Biotechnology stocks.

Key Takeaways

• AMGN is grouped in the Biotechnology sector for peer comparisons.
• Recent beta of 0.42 suggests lower-than-market price sensitivity.
• Trailing profit margin of 21.0% provides context for how much earnings support the headline multiple.

Related Tools & Guides

Explore calculators and guides connected to this metric, or view all metrics for AMGN.

Other AMGN Metrics

Frequently Asked Questions